NicOx SA of France has launched a rights issue of approximately €70 million following the successful completion of a €30 million private placement. An NDA for the company’s lead drug has been filed with the Food and Drug Administration.
Clavis Pharma ASA of Norway has reached an agreement to partner its candidate drug for pancreatic cancer with a start-up oncology company in the US in a deal valued at up to $380 million. The partner is Clovis Oncology Inc of Colorado.
Oxagen Ltd, a privately held UK company researching treatments for inflammation and allergies, has obtained a £16 million, Series C financing from a syndicate led by Novartis Venture Funds.
Newron Pharmaceuticals SpA said that it has raised CHF 7.9 million (€5.2 million) in a private share placement with institutional investors in order to finance its pipeline of new drugs. The company’s lead product is safinamide for Parkinson’s disease.
NicOx SA, a publicly listed French company with a drug for osteoarthritis currently in review at the US Food and Drug Administration, has announced plans to raise fresh capital in a private share placement supported by the French FSI.
Astex Therapeutics Ltd of Cambridge, UK, has concluded a drug discovery deal with GlaxoSmithKline giving GSK access to its fragment chemistry platform. The deal includes upfront and equity investments valued at £20 million.
Sanofi-Aventis said that it has expanded its monoclonal antibody collaboration with Regeneron Pharmaceuticals Inc with a view to bringing four to five new antibody candidates into the clinic per year. It will spend $160 million annually on the project.
Qiagen NV, a Netherlands-based provider of sample and assay technologies, is to acquire the privately-held SABiosciences Corp of the US for $90 million in cash. The deal will give the Dutch company access to assay panels to analyse new drug targets.
Pfizer Inc has decided to pay $1 million for access to a drug delivery technology developed by Flamel Technologies SA of France. The purpose is to develop a controlled-release formulation of a marketed therapeutic protein.
The publicly-traded Swedish speciality pharmaceutical company, Biovitrum AB, has announced plans to merge with closely-held Swedish Orphan International AB to create a new company with SEK 2 billion (€191 million) in revenues and an orphan drug franchise.